The impact of levofloxacin prophylaxis on empiric intravenous antibiotic use in pediatric hematopoietic stem cell transplant recipients.
antimicrobial stewardship
hematopoietic stem cell transplant
levofloxacin
pediatrics
prophylaxis
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
revised:
06
04
2024
received:
03
01
2024
accepted:
23
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
Levofloxacin prophylaxis during periods of neutropenia in pediatric hematopoietic stem cell transplant (HSCT) may reduce the number of febrile episodes and use of empiric intravenous antibiotics (EIA); however, the literature is conflicting. This retrospective review compared EIA use before and after implementation of levofloxacin prophylaxis at a children's hospital. Levofloxacin prophylaxis was associated with reduced use of certain EIA; however, did not reduce the number of positive blood cultures or clinical deteriorations. Therefore, levofloxacin prophylaxis may have implications for the stewardship of broad-spectrum intravenous antibiotics used in pediatric HSCT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31059Informations de copyright
© 2024 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Yang M, Xin L, Li H, et al. Risk factors for bloodstream infection in paediatric haematopoietic stem cell transplantation: a systematic review and meta‐analysis. J Hosp Infect. 2023;139:11‐12. doi:10.1016/j.jhin.2023.06.003
Ziegler M, Landsburg D, Pegues D, et al. Fluoroquinolone prophylaxis is highly effective for the prevention of central line‐associated bloodstream infections in autologous stem cell transplant patients. Biol Blood Marrow Transplant. 2019;25(5):1004‐1010. doi:10.1016/j.bbmt.2018.11.023
Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018;320(10):995‐1004. doi:10.1001/jama.2018.12512
Lehrnbecher T, Fisher BT, Phillips B, et al. Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. Clin Infect Dis. 2020;71(1):226‐236. doi:10.1093/cid/ciz1082
Hafez HA, Yousif D, Abbassi M, et al. Prophylactic levofloxacin in pediatric neutropenic patients during autologous hematopoietic stem cell transplantation. Clin Transplant. 2015;29(12):1112‐1118. doi:10.1111/ctr.12635
Leardini D, Muratore E, Abram N, et al. Effectiveness of quinolone prophylaxis in pediatric acute leukemia and hematopoietic stem cell transplantation: a systematic review and meta‐analysis. Open Forum Infect Dis. 2022;9(12):ofac594. doi:10.1093/ofid/ofac594
Quintero AM, Vidal DAC, Klamer BG, Ardura MI, Oyeniran SJ. Emerging resistance trends in viridans group streptococci bloodstream infections among immunocompromised children receiving levofloxacin prophylaxis. J Pediatric Infect Dis Soc. 2023;12(7):381‐391. doi:10.1093/jpids/piad041 Erratum in: J Pediatric Infect Dis Soc. 2023;12(10):557.
Choi E, Beom J, Ahn H, Park S, Lee H. Incidence and risk factors for QT prolongation associated with fluoroquinolones. J Kor Soc Health‐Sys Pharm. 2023;40(2):195‐210. doi:10.32429/jkshp.2023.40.2.004